ELN guidelines and recommendations
The most visible results of the ELN are the guidelines and management recommendations for virtually every leukemia and interdisciplinary speciality which have lain the groundwork for uniform definitions and standards required for common clinical trials and projects. An update of the collection of the ELN guidelines and recommendations developed since 2006 is now available. ▶ collection of ELN guidelines and recommendations

15th international workshop on CLL
From September 9 to 11, the 15th international workshop on CLL takes place in Cologne, Germany. The forthcoming meeting covers the topics molecular biology, cellular biology, prognostication, novel treatment approaches, stem cell transplantation, and optimising clinical trial design in CLL. ▶ detailed information on the iwCLL 2013

Publications from the Network (selected)

**Acute leukemias**

**Acute lymphoblastic leukemia**
- Ribera JM et al. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: Final results of a phase 2 study (Burkimab). Cancer. 2013 May 1;119(9):1660-8.

**Acute myeloid leukemia**

**Acute myeloid leukemia/myelodysplastic syndromes**

Chronic myeloid leukemia

Chronic lymphocytic leukemia

Chronic myeloproliferative diseases

Myelodysplastic syndromes
- Abouyahya I et al. Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results


**Stem cell transplantation**


**Miscellaneous**


### New trials in the ELTR

**RELIEF** Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes

**I3X-MC-JHTB** A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms

**JAKARTA2** A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated With Ruxolitinib and With a Current Diagnosis of Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

**PIRON01** Iron overload in MDS patients: The value of new iron parameters and MRI T2* of heart and liver as predictor of iron overload

**OCEAN** A non-interventional observational post authorisation study to evaluate safety and efficacy in patients receiving azacitidine in daily clinical practice in the Netherlands